Mercaptopurine 50 mg contains Mercaptopurine (6-MP), an antimetabolite chemotherapy medication used primarily in the treatment of certain blood cancers, especially Acute Lymphoblastic Leukemia (ALL). It works by interfering with the growth and multiplication of abnormal cells and is commonly used as part of long-term maintenance therapy to help prevent disease recurrence. The oral tablet formulation offers convenient administration under the supervision of a healthcare professional.

Mechanism of Action

Mercaptopurine is a purine analog antimetabolite that disrupts the synthesis of nucleic acids required for cell growth and division.

• It is converted inside cells into active metabolites that inhibit the production of purine nucleotides.
• These metabolites interfere with DNA and RNA synthesis, preventing the proliferation of rapidly dividing cells.
• By suppressing the growth of abnormal white blood cells, Mercaptopurine helps control the progression of leukemia and supports remission maintenance.
  

  Uses / Indications

  Mercaptopurine 50 mg is indicated for the treatment of:

  • Acute Lymphoblastic Leukemia (ALL), particularly as maintenance therapy.
  • Certain other hematological malignancies as determined by oncology specialists.
  • Selected autoimmune and inflammatory disorders in specific clinical settings under specialist supervision.

  It is often used in combination with other chemotherapy agents as part of comprehensive cancer treatment protocols.

  Adverse Effects

  Like other chemotherapy medications, Mercaptopurine may cause side effects that require regular monitoring.

  Common Side Effects

  • Bone marrow suppression (reduced white blood cells, red blood cells, and platelets)
  • Increased susceptibility to infections
  • Nausea and vomiting
  • Loss of appetite
  • Fatigue and weakness
  • Mouth ulcers
  • Diarrhea